Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.

Hide

Early diagnostic insights

Receive early diagnostic insights

Our innovative diabetes tests and panels help you and your patients take a proactive approach to preventing and delaying the progression of diabetes.

Insulin resistance

Get ahead while there’s still time—the earlier, the better

Insulin resistance (IR) testing offers significant—and often untapped—clinical value, and it can help you and your patients take action to avoid or change the course of prediabetes and diabetes.1

  • Patients can have normal glucose and HbA1c, but their beta cells may be struggling with glucose load, leading to IR and subsequently prediabetes and diabetes
  • IR can be gradual and difficult to recognize1—patients must be identified while there is still time to reverse course
  • IR is associated with cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), and polycystic ovarian syndrome (PCOS)1

Check for diabetes risk with IR testing from Quest Diagnostics

Quest offers the Cardio IQ® Insulin Resistance Panel with Score, a simple, accurate, and actionable way to assess IR and identify prediabetes and diabetes risk. It’s the only routine insulin resistance score validated against the gold standard.

Learn more about the Cardio IQ® Insulin Resistance Panel with Score

Know what’s ahead—the earlier, the better

Learn More

Metabolic risk testing

Understand the early warning signs of metabolic syndrome—a growing problem

Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.2

Some factors contributing to metabolic syndrome are genetic, while others can be modified with lifestyle changes. Quest Diagnostics offers a full range of testing options to help evaluate patients’ metabolic and cardiovascular risk so physicians can take action to help prevent or delay the onset of chronic conditions such as diabetes and heart disease, and can help prevent adverse events such as stroke.

Metabolic Risk Panel

Point your patients in the right direction, sooner, with the Metabolic Risk Panel

Early identification offers the greatest possibility of success with lifestyle modification. The new Metabolic Risk Panel from Quest Diagnostics Cleveland HeartLab® Cardiometabolic Center of Excellence can help healthcare professionals uncover hidden risk sooner.

Learn more about the Metabolic Risk Panel

Point your clients in the right direction, sooner

Learn More

Metabolic risk and COVID-19

Identifying metabolic risk is key in optimizing patient outcomes should they become infected with COVID-19

A study published in the journal Diabetes Care links metabolic syndrome and severe outcomes from COVID-19, noting significant increases in intensive care admissions, ventilation, acute respiratory distress syndrome (ARDS), and death among patients with metabolic syndrome versus those without metabolic syndrome.3

Early diagnostic insights tests

Insulin resistance

Metabolic risk testing

Metabolic risk & COVID-19

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.


References

  1. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep. 2003;5(5):364-371. doi:10.1007/s11883-003-0007-0
  2. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:E24. doi:10.5888/pcd14.160287
  3. Xie J, Zu Y, Alkhatib A, et al. Metabolic syndrome and COVID-19 mortality among adult black patients in New Orleans Diabetes Care. 2020;44(1):188-193. doi:10.2337/dc20-1714

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More